$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 12 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 10,703 | |
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 160.30 | 502 | 80,471 | 14,065 | 14.6 K to 14.1 K (-3.45 %) |
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 159.62 | 1,698 | 271,038 | 14,567 | 16.3 K to 14.6 K (-10.44 %) |
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 158.45 | 1,590 | 251,939 | 16,265 | 17.9 K to 16.3 K (-8.91 %) |
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 157.28 | 1,000 | 157,283 | 17,855 | 18.9 K to 17.9 K (-5.30 %) |
| Nov 19 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 18,855 | 14.9 K to 18.9 K (+26.93 %) |
| Nov 13 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 21.50 | 2,500 | 53,750 | 6,249 | |
| Nov 13 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 163.27 | 500 | 81,634 | 7,642 | 7.1 K to 7.6 K (+7.00 %) |
| Nov 13 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 173.67 | 1,000 | 173,665 | 7,142 | 6.1 K to 7.1 K (+16.28 %) |
| Nov 13 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 158.18 | 500 | 79,088 | 6,142 | 5.6 K to 6.1 K (+8.86 %) |
| Nov 13 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 21.50 | 2,500 | 53,750 | 5,642 | 3.1 K to 5.6 K (+79.57 %) |
| Nov 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 233 | 5,010 | 10,867 | |
| Nov 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 175.95 | 233 | 40,996 | 2,166 | 2.4 K to 2.2 K (-9.71 %) |
| Nov 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 233 | 5,010 | 2,399 | 2.2 K to 2.4 K (+10.76 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 0.00 | 324 | 0 | 3,142 | 2.8 K to 3.1 K (+11.50 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 146,628 | |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 262.46 | 500 | 131,231 | 479,909 | 480.4 K to 479.9 K (-0.10 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 261.71 | 2,950 | 772,034 | 480,409 | 483.4 K to 480.4 K (-0.61 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 260.68 | 3,166 | 825,300 | 483,359 | 486.5 K to 483.4 K (-0.65 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 259.47 | 1,100 | 285,420 | 486,525 | 487.6 K to 486.5 K (-0.23 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 257.96 | 400 | 103,184 | 487,625 | 488 K to 487.6 K (-0.08 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 256.54 | 200 | 51,308 | 488,025 | 488.2 K to 488 K (-0.04 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 255.30 | 300 | 76,589 | 488,225 | 488.5 K to 488.2 K (-0.06 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 254.29 | 500 | 127,146 | 488,525 | 489 K to 488.5 K (-0.10 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 252.90 | 300 | 75,870 | 489,025 | 489.3 K to 489 K (-0.06 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 250.80 | 384 | 96,308 | 489,325 | 489.7 K to 489.3 K (-0.08 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 249.69 | 100 | 24,969 | 489,709 | 489.8 K to 489.7 K (-0.02 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 247.66 | 100 | 24,766 | 489,809 | 489.9 K to 489.8 K (-0.02 %) |
| Nov 05 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 489,909 | 479.9 K to 489.9 K (+2.08 %) |
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 11,100 | |
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 223.65 | 391 | 87,447 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Oct 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 31.90 | 1,000 | 31,900 | 15,875 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,299 | 0 | 6,490 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 234.87 | 100 | 23,487 | 16,107 | 16.2 K to 16.1 K (-0.62 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 232.92 | 900 | 209,632 | 16,207 | 17.1 K to 16.2 K (-5.26 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 31.90 | 1,000 | 31,900 | 17,107 | 16.1 K to 17.1 K (+6.21 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,299 | 0 | 16,107 | 14.8 K to 16.1 K (+8.77 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 14,703 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 8,113 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 233.97 | 832 | 194,664 | 14,855 | 15.7 K to 14.9 K (-5.30 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 234.01 | 500 | 117,005 | 15,687 | 16.2 K to 15.7 K (-3.09 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 232.97 | 1,000 | 232,965 | 16,187 | 17.2 K to 16.2 K (-5.82 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 232.24 | 1,500 | 348,358 | 17,187 | 18.7 K to 17.2 K (-8.03 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 227.69 | 688 | 156,651 | 18,687 | 19.4 K to 18.7 K (-3.55 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 226.30 | 500 | 113,151 | 19,375 | 19.9 K to 19.4 K (-2.52 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 19,875 | 15.9 K to 19.9 K (+25.20 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 15,875 | 14.3 K to 15.9 K (+11.38 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 3,245 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 8,762 | 8.1 K to 8.8 K (+8.00 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 156,628 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,867 | 0 | 24,339 | |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 234.94 | 200 | 46,987 | 479,909 | 480.1 K to 479.9 K (-0.04 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 233.74 | 100 | 23,374 | 480,109 | 480.2 K to 480.1 K (-0.02 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 232.15 | 300 | 69,645 | 480,209 | 480.5 K to 480.2 K (-0.06 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 231.31 | 700 | 161,920 | 480,509 | 481.2 K to 480.5 K (-0.15 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 230.30 | 600 | 138,181 | 481,209 | 481.8 K to 481.2 K (-0.12 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 229.30 | 1,750 | 401,272 | 481,809 | 483.6 K to 481.8 K (-0.36 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 228.45 | 3,500 | 799,579 | 483,559 | 487.1 K to 483.6 K (-0.72 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 227.64 | 1,450 | 330,082 | 487,059 | 488.5 K to 487.1 K (-0.30 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 226.53 | 1,400 | 317,147 | 488,509 | 489.9 K to 488.5 K (-0.29 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 489,909 | 479.9 K to 489.9 K (+2.08 %) |
| Oct 03 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,867 | 0 | 479,909 | 475 K to 479.9 K (+1.02 %) |
| Sep 17 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 18,703 | |
| Sep 17 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 286.75 | 1,000 | 286,750 | 14,253 | 15.3 K to 14.3 K (-6.56 %) |
| Sep 17 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 279.33 | 3,000 | 838,001 | 15,253 | 18.3 K to 15.3 K (-16.44 %) |
| Sep 17 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 18,253 | 14.3 K to 18.3 K (+28.06 %) |
| Sep 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 11,491 | |
| Sep 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 280.50 | 391 | 109,676 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Sep 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 166,628 | |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 289.72 | 200 | 57,943 | 475,042 | 475.2 K to 475 K (-0.04 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 288.17 | 800 | 230,532 | 475,242 | 476 K to 475.2 K (-0.17 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 287.48 | 1,600 | 459,969 | 476,042 | 477.6 K to 476 K (-0.33 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 286.42 | 3,800 | 1,088,410 | 477,642 | 481.4 K to 477.6 K (-0.79 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 285.56 | 3,600 | 1,028,028 | 481,442 | 485 K to 481.4 K (-0.74 %) |
| Sep 04 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 485,042 | 475 K to 485 K (+2.11 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 10,000 | 86,667 | 30,131 | |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 296.14 | 700 | 207,295 | 14,253 | 15 K to 14.3 K (-4.68 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 295.61 | 1,200 | 354,732 | 14,953 | 16.2 K to 15 K (-7.43 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 293.89 | 4,250 | 1,249,025 | 16,153 | 20.4 K to 16.2 K (-20.83 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 293.05 | 3,850 | 1,128,233 | 20,403 | 24.3 K to 20.4 K (-15.87 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 10,000 | 86,667 | 24,253 | 14.3 K to 24.3 K (+70.16 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 295.13 | 1,000 | 295,125 | 1,465 | 2.5 K to 1.5 K (-40.57 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 295.04 | 1,433 | 422,794 | 2,465 | 3.9 K to 2.5 K (-36.76 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 302.34 | 400 | 120,936 | 1,485,324 | 1.5 M to 1.5 M (-0.03 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 301.36 | 5,400 | 1,627,344 | 1,485,724 | 1.5 M to 1.5 M (-0.36 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 300.11 | 45,058 | 13,522,356 | 1,491,124 | 1.5 M to 1.5 M (-2.93 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 299.13 | 10,400 | 3,110,952 | 1,536,182 | 1.5 M to 1.5 M (-0.67 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 297.26 | 1,990 | 591,547 | 1,546,582 | 1.5 M to 1.5 M (-0.13 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.59 | 10,010 | 2,968,866 | 1,548,572 | 1.6 M to 1.5 M (-0.64 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 295.52 | 25,442 | 7,518,620 | 1,558,582 | 1.6 M to 1.6 M (-1.61 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.67 | 12,558 | 3,700,466 | 1,584,024 | 1.6 M to 1.6 M (-0.79 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 308.13 | 350 | 107,844 | 1,596,582 | 1.6 M to 1.6 M (-0.02 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 307.06 | 14,640 | 4,495,314 | 1,596,932 | 1.6 M to 1.6 M (-0.91 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 306.23 | 525 | 160,772 | 1,611,572 | 1.6 M to 1.6 M (-0.03 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 305.14 | 1,732 | 528,501 | 1,612,097 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 303.77 | 1,193 | 362,394 | 1,613,829 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 302.55 | 1,100 | 332,806 | 1,615,022 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 301.42 | 1,710 | 515,426 | 1,616,122 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 300.21 | 3,985 | 1,196,329 | 1,617,832 | 1.6 M to 1.6 M (-0.25 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 298.61 | 100 | 29,861 | 1,621,817 | 1.6 M to 1.6 M (-0.01 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 297.76 | 9,985 | 2,973,134 | 1,621,917 | 1.6 M to 1.6 M (-0.61 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.86 | 6,192 | 1,838,139 | 1,631,902 | 1.6 M to 1.6 M (-0.38 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.21 | 7,062 | 2,091,814 | 1,638,094 | 1.6 M to 1.6 M (-0.43 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.96 | 3,254 | 959,800 | 1,645,156 | 1.6 M to 1.6 M (-0.20 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 293.85 | 4,468 | 1,312,908 | 1,648,410 | 1.7 M to 1.6 M (-0.27 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 292.70 | 3,704 | 1,084,165 | 1,652,878 | 1.7 M to 1.7 M (-0.22 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.34 | 400 | 120,936 | 1,485,324 | 1.5 M to 1.5 M (-0.03 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.36 | 5,400 | 1,627,344 | 1,485,724 | 1.5 M to 1.5 M (-0.36 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.11 | 45,058 | 13,522,356 | 1,491,124 | 1.5 M to 1.5 M (-2.93 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 299.13 | 10,400 | 3,110,952 | 1,536,182 | 1.5 M to 1.5 M (-0.67 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.26 | 1,990 | 591,547 | 1,546,582 | 1.5 M to 1.5 M (-0.13 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.59 | 10,010 | 2,968,866 | 1,548,572 | 1.6 M to 1.5 M (-0.64 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 295.52 | 25,442 | 7,518,620 | 1,558,582 | 1.6 M to 1.6 M (-1.61 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.67 | 12,558 | 3,700,466 | 1,584,024 | 1.6 M to 1.6 M (-0.79 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 308.13 | 350 | 107,844 | 1,596,582 | 1.6 M to 1.6 M (-0.02 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 307.06 | 14,640 | 4,495,314 | 1,596,932 | 1.6 M to 1.6 M (-0.91 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 306.23 | 525 | 160,772 | 1,611,572 | 1.6 M to 1.6 M (-0.03 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 305.14 | 1,732 | 528,501 | 1,612,097 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 303.77 | 1,193 | 362,394 | 1,613,829 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.55 | 1,100 | 332,806 | 1,615,022 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.42 | 1,710 | 515,426 | 1,616,122 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.21 | 3,985 | 1,196,329 | 1,617,832 | 1.6 M to 1.6 M (-0.25 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 298.61 | 100 | 29,861 | 1,621,817 | 1.6 M to 1.6 M (-0.01 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.76 | 9,985 | 2,973,134 | 1,621,917 | 1.6 M to 1.6 M (-0.61 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.86 | 6,192 | 1,838,139 | 1,631,902 | 1.6 M to 1.6 M (-0.38 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.21 | 7,062 | 2,091,814 | 1,638,094 | 1.6 M to 1.6 M (-0.43 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.96 | 3,254 | 959,800 | 1,645,156 | 1.6 M to 1.6 M (-0.20 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 4,468 | 1,312,908 | 1,648,410 | 1.7 M to 1.6 M (-0.27 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.70 | 3,704 | 1,084,165 | 1,652,878 | 1.7 M to 1.7 M (-0.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 22,703 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 292.16 | 4,000 | 1,168,656 | 14,253 | 18.3 K to 14.3 K (-21.91 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 288.00 | 774 | 222,912 | 18,253 | 19 K to 18.3 K (-4.07 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 19,027 | 15 K to 19 K (+26.62 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | M | 37.69 | 8,124 | 306,194 | 101,875 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 346.68 | 224 | 77,656 | 1,410 | 1.6 K to 1.4 K (-13.71 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 344.73 | 500 | 172,366 | 1,634 | 2.1 K to 1.6 K (-23.43 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 343.80 | 800 | 275,039 | 2,134 | 2.9 K to 2.1 K (-27.27 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 342.05 | 300 | 102,614 | 2,934 | 3.2 K to 2.9 K (-9.28 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 341.21 | 300 | 102,362 | 3,234 | 3.5 K to 3.2 K (-8.49 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 337.17 | 100 | 33,717 | 3,534 | 3.6 K to 3.5 K (-2.75 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 336.47 | 200 | 67,293 | 3,634 | 3.8 K to 3.6 K (-5.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 335.02 | 100 | 33,502 | 3,834 | 3.9 K to 3.8 K (-2.54 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 331.92 | 200 | 66,384 | 3,934 | 4.1 K to 3.9 K (-4.84 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 330.91 | 206 | 68,167 | 4,134 | 4.3 K to 4.1 K (-4.75 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 329.59 | 594 | 195,777 | 4,340 | 4.9 K to 4.3 K (-12.04 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 327.89 | 300 | 98,366 | 4,934 | 5.2 K to 4.9 K (-5.73 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 326.03 | 100 | 32,603 | 5,234 | 5.3 K to 5.2 K (-1.87 %) |